Home Cannabis GW Pharmaceuticals Has Already Soared 23% in January

GW Pharmaceuticals Has Already Soared 23% in January

Stock performance

On January 9, GW Pharmaceuticals (GWPH) stock rose ~1.81% to reach $119.54 from its prior day close of $117.41 on January 8. On January 7, the company’s stock price grew ~5.31% to reach $114.66 from its prior day close of $108.66 on January 4, 2019. On January 4, the company’s stock grew ~9.22% to reach $108.88 from its prior day close of $99.69 on January 3, 2019.

GW Pharmaceuticals’ price of $119.54 on January 9 represents ~23% growth in the first six trading days of January 2, and this price is 33% below its 52-week high of $179.65 on September 27, 2018. On December 27, 2018, the company hit its 52-week low of $90.14.

GWPH

About GW Pharmaceuticals

GW Pharmaceuticals is focused on the innovation, development, and commercialization of therapies from the company’s proprietary cannabinoid products. GW Pharmaceuticals’ Epidiolex oral solution has already received the FDA (Food and Drug Administration) approval for the treatment of individuals aged above two years with seizures related to Lennox-Gastaut syndrome or Dravet Syndrome.

Analysts’ recommendations

Of 13 analysts tracking GW Pharmaceuticals (GWPH) in January 2019, three of them recommended a “strong buy,” while eight analysts recommended a “buy” rating. One analyst recommended a “hold” rating, while one analyst recommended a “strong sell” for GW Pharmaceuticals in January.

- Advertisement -

On January 10, GW Pharmaceuticals had a consensus 12-month target price of $173.17, which represents a ~44.86% return on investment over the next 12 months of this year.

Peer ratings

Of the five analysts tracking Supreme Cannabis Company (SPRWF) in January 2019, two of them recommended a “strong buy,” while three analysts recommended a “buy” rating.

In January 2019, of the 11 analysts tracking Canopy Growth (CGC), two of them recommended a “strong buy,” seven recommended a “buy,” one recommended a “hold,” and one recommended a “sell” rating.

Must Read